leisure time -WSS

leisure time

author：explore 2025-09-28 00:51:31 - browse：82968

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Interest rates are at a 22

focus

WSS

Congress might make insulin pumps more accessible to the blind

Abbott's new heart device gets FDA advisory panel nod

Biden announces an advanced cancer research initiative

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Trump allegedly attempted to have surveillance video deleted: Special Counsel

leisure time

leisure time

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

Resistance to opioid

The high cost of giving birth even with insurance

As the dark side of IVF slowly comes into focus, even more transparency is needed

BioMarin wins approval for gene therapy to treat hemophilia A

Here’s what’s in the FDA plan to include pregnant women in clinical trials

How to save PrEP access — and even expand it

Juul documents reveal insider tactics on political lobbying

Wildfire smoke exposes gaps in outdoor worker protections

Ending health disparities requires full federal government, panel says

entertainment

Doctors on social media are being harassed and cyberbullied

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Too many hospitalized Covid

Public health communication lessons from Covid

Why Eli Lilly’s earnings didn’t quite live up to the hype

AMAs digital advisors table RPM coding reform proposal, again

entertainment

focus

entertainment

knowledge